B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 1.792 NOK 1.59% Market Closed
Market Cap: 70m NOK
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one BGBIO stock under the Base Case scenario is 0.203 NOK. Compared to the current market price of 1.792 NOK, Bergenbio ASA is Overvalued by 89%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BGBIO Relative Value
Base Case
0.203 NOK
Overvaluation 89%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

82.6
P/S
P/S
Price to Sales
82.6
vs History
96
vs Industry
17
Median 3Y
72 013.1
Median 5Y
1 047 336.9
Industry
7
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-102.1
Median 5Y
-1 969.5
Industry
21.8
Forward
-0.6
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-96.8
Median 5Y
-1 993.1
Industry
19.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-96.8
Median 5Y
-1 990.6
Industry
22.7
More Details
0.6
P/B
P/B
Price to Book Value
0.6
vs History
96
vs Industry
71
Median 3Y
154.7
Median 5Y
2 729.4
Industry
2.4
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
4
Median 3Y
71 827.1
Median 5Y
1 046 960.3
Industry
7.3
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.8
More Details
0.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
0.5
vs History
1
vs Industry
23
Median 3Y
-100.8
Median 5Y
-1 957
Industry
4
Forward
0.6
More Details
0.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
0.5
vs History
1
vs Industry
21
Median 3Y
-100.7
Median 5Y
-1 949.8
Industry
3.7
Forward
0.8
More Details
0.5
EV/OCF
EV/OCF
Enterprise Value to OCF
0.5
vs History
1
vs Industry
25
Median 3Y
-96.5
Median 5Y
-1 992.3
Industry
4.5
More Details
0.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
0.5
vs History
1
vs Industry
21
Median 3Y
-96.5
Median 5Y
-1 992.3
Industry
3.2
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
3
Median 3Y
-855.3
Median 5Y
-36 285.9
Industry
4.5
More Details

Multiples Across Competitors

BGBIO Competitors Multiples
Bergenbio ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Bergenbio ASA
OSE:BGBIO
70m NOK 82.6 -0.5 0.5 0.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 893 126.3 -165 841.9 -201 384.9 -199 086.8
US
Abbvie Inc
NYSE:ABBV
328.4B USD 5.8 77.5 15.4 23.2
US
Amgen Inc
NASDAQ:AMGN
150.8B USD 4.5 36.9 15.2 26.9
US
Gilead Sciences Inc
NASDAQ:GILD
128.5B USD 4.5 267.8 10.6 13.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.9B USD 11.5 -236.9 25.9 27.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 019 -515.2 -561 -546
AU
CSL Ltd
ASX:CSL
117.1B AUD 4.9 27.3 16.9 21.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
66B USD 4.7 15 9.4 10.5
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.6 -64.2 -58
NL
argenx SE
XBRU:ARGX
32.7B EUR 17 44.6 -2 522 -1 690.9
P/S Multiple
Revenue Growth P/S to Growth
NO
B
Bergenbio ASA
OSE:BGBIO
Average P/S: 3 172 300
82.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 893 126.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
7%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.5
10%
1.2
US
E
Epizyme Inc
F:EPE
2 019
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.7
6%
0.8
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
17
39%
0.4
P/E Multiple
Earnings Growth PEG
NO
B
Bergenbio ASA
OSE:BGBIO
Average P/E: 78.2
Negative Multiple: -0.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 841.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.5
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
36.9
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
267.8
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -236.9 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -515.2 N/A N/A
AU
CSL Ltd
ASX:CSL
27.3
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
NL
argenx SE
XBRU:ARGX
44.6
28%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
B
Bergenbio ASA
OSE:BGBIO
Average EV/EBITDA: 13.4
0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 384.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
15.2
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.6
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.9
18%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -561 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.4
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.2 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 522 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
B
Bergenbio ASA
OSE:BGBIO
Average EV/EBIT: 17.5
0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 086.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.9
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.2
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -546 N/A N/A
AU
CSL Ltd
ASX:CSL
21.1
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.5
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -58 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 690.9 N/A N/A

See Also

Summary
BGBIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
BGBIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BGBIO stock valuation using valuation multiples.
Wall Street Estimates
BGBIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BGBIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 249,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.